YOU ARE ABOUT TO EXIT A GLOBAL HEMANEXT ONE PRODUCT WEBSITE FOR THE US HEMANEXT CORPORATE WEBSITE
Please be aware that the website you have requested is intended for the residents of the United States. The Hemanext One® System has not been cleared, approved, or otherwise authorized by the US Food & Drug Administration for commercial distribution in the United States.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
LEXINGTON, Mass., January 24, 2022, PR NEWSWIRE – Hemanext Inc. today announced that Hemanext ONE®, its innovative blood processing and storage system, has been recognized by the Association for the Advancement of Blood & Biotherapies (“AABB”), a...
Research supports Hemanext’s aim to improve clinical outcomes of transfusion recipients with its innovative red blood cell processing and storage system. LEXINGTON, Mass., September 21, 2021, PR NEWSWIRE – Hemanext Inc. (“Hemanext” or the...
Senior Director of Transfusion Medicine at Johns Hopkins University Brings Global Experience in Transfusion Medicine and Research Company Recently Received CE Mark Certification for Innovative Red Blood Cell Processing and Storage System LEXINGTON, Mass., Aug 3, 2021,...
Sickle Cell Disease (SCD) Affects Over 20M Worldwide, including 100K Americans1,2 LEXINGTON, MA and SAN FRANCISCO, CA – Jul 28, 2021 – Hemanext Inc. a privately held, US-based medical technology company dedicated to improving the quality, safety, efficacy, and cost of...
Hemanext® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System Company to launch Hemanext ONE® RBC Processing and Storage System in select European markets in 2021, with wider distribution in Europe and the Americas...
